HNP1
HNP1 (human neutrophil peptide 1) is an alpha-defensin antimicrobial peptide produced by neutrophils and studied for membrane-active antibacterial effects and synergy with other innate peptides.
Tag
Pages related to Infectious disease.
HNP1 (human neutrophil peptide 1) is an alpha-defensin antimicrobial peptide produced by neutrophils and studied for membrane-active antibacterial effects and synergy with other innate peptides.
LL-37 (cathelicidin) is a human antimicrobial peptide involved in innate immune defense and widely studied for membrane-active antibacterial and immunomodulatory effects.
Dermcidin is a human antimicrobial peptide found in sweat and other tissues. A 2026 study reported antiviral activity against influenza via binding hemagglutinin, with mouse protection data.
A novel antimicrobial peptide reported in 2026 to have activity against carbapenem-resistant Acinetobacter baumannii in vitro and in mouse infection models.
A preprint suggests a simple chemical add-on can make a short LL-37 fragment more bacteria-killing, hinting at a reusable design rule for antimicrobial peptides.
A new mechanistic study suggests LL-37 and HNP1 can form reversible aggregates that become more active on bacterial-like membranes while staying less toxic to human cells.
A 2026 PNAS paper reports constrained bicyclic peptides, inspired by the FI6v3 antibody HCDR3, that bind the conserved hemagglutinin stem and neutralize multiple influenza A subtypes in vitro.
A PNAS study reports that dermcidin, an antimicrobial peptide found in sweat, can bind influenza hemagglutinin, inhibit infection in vitro, and protect mice, with higher levels seen in asymptomatic humans.
A 2026 *Virulence* paper reports that lachnospirin‑1 killed carbapenem-resistant *A. baumannii*, disrupted biofilms and persisters, and showed efficacy in mouse infection models. It is still preclinical, but it has the kind of signal package that can justify deeper development.